ArticleLeukemia & lymphoma2020

Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.

Elizabeth DiMaggio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.